X Bioscience Public Company Limited Statistics
X Bioscience Public Company Limited (XBIO) Stock Statistics & Valuation Metrics
Total Valuation
X Bioscience Public Company Limited has a market cap or net worth of THB 488.63M. The enterprise value is THB 451.67M.
- Market Cap
- THB 488.63M
- Enterprise Value
- THB 451.67M
Share Statistics
X Bioscience Public Company Limited has 12,215,699,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 12,215,699,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
X Bioscience Public Company Limited’s return on equity (ROE) is -2.16 and return on invested capital (ROIC) is -93.16%.
- Return on Equity (ROE)
- -2.16
- Return on Assets (ROA)
- -0.77
- Return on Invested Capital (ROIC)
- -93.16%
- Return on Capital Employed (ROCE)
- -1.60
- Revenue Per Employee
- 324.67K
- Profits Per Employee
- -1.18M
- Employee Count
- 399
- Asset Turnover
- 0.21
- Inventory Turnover
- 34.51
Valuation Ratios
The current PE Ratio of X Bioscience Public Company Limited is -0.17. X Bioscience Public Company Limited’s PEG ratio is -0.00.
- PE Ratio
- -0.17
- PS Ratio
- 0.38
- PB Ratio
- 0.51
- Price to FCF
- -0.24
- Price to Operating Cash Flow
- -0.93
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, X Bioscience Public Company Limited had revenue of 129.55M and earned -468.87M in profits. Earnings per share was -0.62.
- Revenue
- 129.55M
- Gross Profit
- 52.93M
- Operating Income
- -454.41M
- Pretax Income
- -455.74M
- Net Income
- -468.87M
- EBITDA
- -414.35M
- Earnings Per Share (EPS)
- -0.62
Cash Flow
In the last 12 months, operating cash flow was -161.89M and capital expenditures -172.82M, giving a free cash flow of -334.71M billion.
- Operating Cash Flow
- -161.89M
- Free Cash Flow
- -334.71M
- Free Cash Flow per Share
- -0.09
Dividends & Yields
X Bioscience Public Company Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -424.04%
- Earnings Yield
- -456.26%
Stock Price Statistics
- Beta
- 1.27
- 52-Week Price Change
- -63.96%
- 50-Day Moving Average
- 0.06
- 200-Day Moving Average
- 0.07
- Relative Strength Index (RSI)
- 24.57
- Average Volume (3m)
- 2.73M
Important Dates
X Bioscience Public Company Limited upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 16, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
X Bioscience Public Company Limited as a current ratio of 0.93, with Debt / Equity ratio of 110.96%
- Current Ratio
- 0.93
- Quick Ratio
- 0.92
- Debt to Market Cap
- 1.48
- Net Debt to EBITDA
- -0.58
- Interest Coverage Ratio
- -17.33
Taxes
In the past 12 months, X Bioscience Public Company Limited has paid -3.25M in taxes.
- Income Tax
- -3.25M
- Effective Tax Rate
- 0.01
Enterprise Valuation
X Bioscience Public Company Limited EV to EBITDA ratio is -0.24, with an EV/FCF ratio of -0.61.
- EV to Sales
- 0.97
- EV to EBITDA
- -0.24
- EV to Free Cash Flow
- -0.61
- EV to Operating Cash Flow
- -1.25
Balance Sheet
X Bioscience Public Company Limited has THB 5.29M in cash and marketable securities with THB 129.25M in debt, giving a net cash position of -THB 123.96M billion.
- Cash & Marketable Securities
- THB 5.29M
- Total Debt
- THB 129.25M
- Net Cash
- -THB 123.96M
- Net Cash Per Share
- -THB 0.01
- Tangible Book Value Per Share
- THB 0.07
Margins
Gross margin is 39.93%, with operating margin of -417.53%, and net profit margin of -329.74%.
- Gross Margin
- 39.93%
- Operating Margin
- -417.53%
- Pretax Margin
- -336.76%
- Net Profit Margin
- -329.74%
- EBITDA Margin
- -401.00%
- EBIT Margin
- -416.52%
Analyst Forecast
The average price target for X Bioscience Public Company Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -19.69%
- EPS Growth Forecast
- 37.65%
